Changeflow GovPing Pharma & Drug Safety Rapamycin resistant cells
Routine Notice Added Final

Rapamycin resistant cells

Favicon for changeflow.com USPTO Patent Grants - Biotech (C12N)
Published
Detected
Email

Summary

Seattle Children's Hospital has been granted US Patent 12595492B2 for rapamycin resistant cell compositions and methods. The patent covers proteins expressed in host cells to confer rapamycin resistance, with applications in modulating cell signaling and selective cell expansion. The patent contains 32 claims with six named inventors including Andrew M. Scharenberg and David J. Rawdings.

What changed

USPTO granted Patent No. 12595492B2 to Seattle Children's Hospital on April 7, 2026, covering compositions and methods for rendering host cells resistant to rapamycin, including proteins, cells, and methods for modulating cell signaling and selective cell expansion. The patent application was filed on April 10, 2024, under application number 18631675.

Affected parties including biotechnology firms, pharmaceutical companies, and research institutions should monitor this patent for freedom-to-operate considerations when developing cell-based therapies or research involving rapamycin-resistant cell lines. The patent may impact licensing negotiations and R&D strategies in the cell therapy and immunotherapy spaces.

What to do next

  1. Monitor for updates
  2. Review patent claims for potential infringement concerns

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Rapamycin resistant cells

Grant US12595492B2 Kind: B2 Apr 07, 2026

Assignee

Seattle Children's Hospital

Inventors

Andrew M. Scharenberg, David J. Rawlings, Karen Sommer, Samuel West, Yuchi Chiang Honaker, Ryo Takeuchi

Abstract

The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

CPC Classifications

C12N 15/90

Filing Date

2024-04-10

Application No.

18631675

Claims

32

View original document →

Get daily alerts for USPTO Patent Grants - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12595492B2

Who this affects

Applies to
Drug manufacturers Healthcare providers Research institutions
Industry sector
3254.1 Biotechnology
Activity scope
Patent licensing Cell therapy R&D Biotechnology research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!